Multimedia
 | Media file 1: Classic histologic image of oligodendroglioma. This image shows monomorphous tumoral proliferation that consists of round, regular cells with a small, central, hyperchromatic nucleus surrounded by clear cytoplasm. Few calcifications are present. |
 | Media file 2: Smear preparation of well-differentiated oligodendroglioma. This image reveals isolated tumoral cells with regular, round nuclei. |
 | Media file 3: Paraffin section of well-differentiated oligodendroglioma (same case as in Image 2). This image shows tumoral cells, some reactional astrocytes, and an absence of vascular proliferation. |
 | Media file 4: Smear preparation of anaplastic oligodendroglioma. This image reveals increased nuclear pleomorphism and vascular proliferation. |
 | Media file 5: Paraffin section of anaplastic oligodendroglioma (same case as in Image 4). This image shows dense tumoral proliferation with round nuclei, perinuclear halos, calcification, and endothelial hyperplasia. |
 | Media file 6: Lateral radiograph of the skull in a 44-year-old man with a 3-year history of epileptic seizures. This radiograph shows a left frontal oligodendroglioma. Note the vermicular calcifications that are projecting on the frontal lobe. |
 | Media file 7: Contrast-enhanced computed tomography scan in a 44-year-old man with a 3-year history of epileptic seizures (same patient as in Image 6). This image reveals a calcified hypoattenuating lesion that is invading the corpus callosum. |
 | Media file 8: Contrast-enhanced computed tomography scan in a 50-year-old man. This image reveals recurrence of a frontal oligodendroglioma in the right basal ganglia that was excised 6 years earlier. |
 | Media file 9: Computed tomography scan of a low-grade oligodendroglioma. (Same patient as in the 3 MRI Images that follow.) This image reveals a well-demarcated, left frontal hypoattenuating lesion with a small calcification. |
 | Media file 10: Axial fluid-attenuated inversion recovery magnetic resonance of a low-grade oligodendroglioma (same patient as in Image above and 2 Images that follow). This image shows heterogeneous high signal intensity in the left frontal lobe. |
 | Media file 11: Axial T1-weighted magnetic resonance image of a low-grade oligodendroglioma (same patient as in the 2 Images above and the Image below). This image shows heterogeneous low signal intensity in the left frontal lobe that involves the cortex and white matter. Note the mass effect on the cortical sulci. |
 | Media file 12: Sagittal gadolinium-enhanced T1-weighted magnetic resonance image of a low-grade oligodendroglioma (same patient as in the 3 Images above). This image demonstrates no contrast enhancement. |
 | Media file 13: Computed tomography scan of a low-grade oligodendroglioma. This image shows left frontal hypoattenuation that mainly involves the white matter. |
 | Media file 14: Sagittal T1-weighted sequence magnetic resonance of a low-grade oligodendroglioma (same patient as in Images 13 and 15-18). This image shows heterogeneous low signal intensity involving the frontal lobe. Note the involvement of the corpus callosum. |
 | Media file 15: Sagittal gadolinium-enhanced T1-weighted magnetic resonance image of a low-grade oligodendroglioma (same patient as in Images 13-14, 16-18). This image shows a huge infiltrative lesion in the frontal lobe, no contrast enhancement, and a mass effect on the cortical sulci. |
 | Media file 16: Axial T2-weighted sequence magnetic resonance image of a low-grade oligodendroglioma (same patient as in Images 13-15, 17-18). This image shows heterogeneous high signal intensity in the left frontal lobe and low signal intensity in the white matter of the right parietal lobe that corresponds to a cavernous hemangioma. |
 | Media file 17: Axial gadolinium-enhanced T1-weighted magnetic resonance image of anaplastic transformation of a low-grade oligodendroglioma, 4 years later (same patient as in Images 13-16, 18). This image depicts local recurrence after surgery, with contrast enhancement in the left frontal lobe. |
 | Media file 18: Axial gadolinium-enhanced T1-weighted magnetic resonance image of anaplastic transformation of a low-grade oligodendroglioma, 4 years later (same patient as in Images 13-17). This image shows multifocal recurrence. A contrast-enhanced tumoral nodule is seen in the right temporal lobe. Note the left retro-ocular cavernous hemangioma. |
 | Media file 19: Axial gadolinium-enhanced T1-weighted magnetic resonance image of an anaplastic oligodendroglioma. This image shows heterogeneous contrast enhancement in the medial part of the left parieto-rolandic region. |
 | Media file 20: Axial T1-weighted gadolinium-enhanced magnetic resonance image of an anaplastic oligodendroglioma, 2 months after chemotherapy (same patient as in Image 19). This image shows disappearance of the contrast enhancement. |
 | Media file 21: Computed tomography scan of a low-grade oligodendroglioma. (Same patient as in the angiograph below.) This image shows hypoattenuation of the left frontal lobe without contrast enhancement. |
 | Media file 22: Lateral carotid angiograph of a low-grade oligodendroglioma (same patient as in the Image above). This image shows a vascular void due to the tumor. |
More on Oligodendroglioma |
| Overview: Oligodendroglioma |
| Imaging: Oligodendroglioma |
 Multimedia: Oligodendroglioma |
| References |
| Further Reading |
| « Previous Page |
References
Blakeley J, Grossman S. Anaplastic oligodendroglioma. Curr Treat Options Neurol. Jul 2008;10(4):295-307. [Medline].
Zustovich F, Della Puppa A, Scienza R, Anselmi P, Furlan C, Cartei G. Metastatic oligodendrogliomas: a review of the literature and case report. Acta Neurochir (Wien). Jul 2008;150(7):699-702; discussion 702-3. [Medline].
Bailey P, Hiller G. The interstitial tissues of the central nervous system: a review. J Nerv Ment Dis. 1924;59:337-61.
Bailey P, Cushing H. A Classification of the Tumors of the Glioma Group on a Histogenetic Basis With a Correlated Study of Prognosis. Philadelphia, Pa: J.B. Lippincott; 1926:105-65.
Bailey P, Bucy PC. Oligodendrogliomas of the brain. J Pathol Bacteriol. 1929;32:735-51.
Central Brain Tumor Registry of the United States (CBTRUS). Statistical Report: Primary Brain Tumors in the United States, 1998-2002. Hinsdale, Ill: CBTRUS; 2005-2006:19, 34. [Full Text].
Jenkinson MD, Smith TS, Joyce KA, et al. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology. Oct 2006;48(10):703-13. [Medline]. [Full Text].
Koeller KK, Rushing EJ. From the archives of the AFIP: Oligodendroglioma and its variants: radiologic-pathologic correlation. Radiographics. Nov-Dec 2005;25(6):1669-88. [Medline]. [Full Text].
Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer. Feb 15 2005;103(4):802-9. [Medline].
Thiessen B, Maguire JA, McNeil K, et al. Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol. Sep 2003;64(3):271-8. [Medline].
Packer RJ, Sutton LN, Rorke LB, et al. Oligodendroglioma of the posterior fossa in childhood. Cancer. Jul 1 1985;56(1):195-9. [Medline].
Daumas-Duport C, Beuvon F, Varlet P, Fallet-Bianco C. [Gliomas: WHO and Sainte-Anne Hospital classifications]. [French]. Ann Pathol. Oct 2000;20(5):413-28. [Medline].
Daumas-Duport C, Varlet P, Tucker ML, et al. Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol. Aug 1997;34(1):37-59. [Medline].
Daumas-Duport C, Tucker ML, Kolles H, et al. Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria. J Neurooncol. Aug 1997;34(1):61-78. [Medline].
Abrey LE, Louis DN, Paleologos N, et al. Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol. Jul 2007;9(3):314-8. [Medline].
Hottinger AF, Stupp R. [Therapeutic strategies for the management of gliomas]. Rev Neurol (Paris). Jun-Jul 2008;164(6-7):523-30. [Medline].
Margain D, Peretti-Viton P, Perez-Castillo AM, Martini P, Salamon G. Oligodendrogliomas. J Neuroradiol. 1991;18(2):153-60. [Medline].
Kawai N, Kagawa M, Hatakeyama T, Tamiya T, Noshiyama Y, Yamamoto Y, et al. [11C-methionine positron emission tomography in brain tumor]. No Shinkei Geka. Oct 2008;36(10):847-59. [Medline].
Brown R, Zlatescu M, Sijben A, Roldan G, Easaw J, Forsyth P, et al. The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res. Apr 15 2008;14(8):2357-62. [Medline].
Cha S, Tihan T, Crawford F, et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol. Feb 2005;26(2):266-73. [Medline]. [Full Text].
White ML, Zhang Y, Kirby P, Ryken TC. Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?. AJNR Am J Neuroradiol. Apr 2005;26(4):784-90. [Medline]. [Full Text].
Peretti-Viton P, Taieb D, Viton JM, et al. Contrast-enhanced magnetisation transfer MRI in metastatic lesions of the brain. Neuroradiology. Dec 1998;40(12):783-7. [Medline].
Jäger HR, Waldman AD, Benton C, Fox N, Rees J. Differential chemosensitivity of tumor components in a malignant oligodendroglioma: assessment with diffusion-weighted, perfusion-weighted, and serial volumetric MR imaging. AJNR Am J Neuroradiol. Feb 2005;26(2):274-8. [Medline]. [Full Text].
Albert FK, Forsting M, Sartor K, Adams HP, Kunze S. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. Jan 1994;34(1):45-60; discussion 60-1. [Medline].
Bullard DE, Rawlings CE 3rd, Phillips B, et al. Oligodendroglioma. An analysis of the value of radiation therapy. Cancer. Nov 1 1987;60(9):2179-88. [Medline].
Burger PC. Revising the World Health Organization (WHO) Blue Book--'Histological typing of tumours of the central nervous system'. J Neurooncol. 1995;24(1):3-7. [Medline].
Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol. Apr 1988;23(4):360-4. [Medline].
Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. Oct 7 1998;90(19):1473-9. [Medline].
Celli P, Nofrone I, Palma L, Cantore G, Fortuna A. Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery. Dec 1994;35(6):1018-34; discussion 1034-5. [Medline].
Chin HW, Hazel JJ, Kim TH, Webster JH. Oligodendrogliomas. I. A clinical study of cerebral oligodendrogliomas. Cancer. Mar 15 1980;45(6):1458-66. [Medline].
Couldwell WT, Hinton DR. Oligodendroglioma. In: Kaye AH, Laws ER Jr, ed. Brain Tumors: an Encyclopedic Approach. New York, NY: Churchill Livingstone; 1995:479-91.
Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer. Nov 15 1988;62(10):2152-65. [Medline].
Gonzales MF. Classification and pathogenesis of brain tumors. In: Kaye AH and Laws ER Jr, eds. Brain Tumors: an Encyclopedic Approach. New York, NY: Churchill Livingstone; 1995:31-42.
Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. Jul 1993;3(3):255-68. [Medline].
Kros JM. Oligodendrogliomas: clinicopathological correlations. J Neurooncol. 1995;24(1):29-31. [Medline].
Lee YY, Van Tassel P. Intracranial oligodendrogliomas: imaging findings in 35 untreated cases. AJR Am J Roentgenol. Feb 1989;152(2):361-9. [Medline]. [Full Text].
Lindegaard KF, Mørk SJ, Eide GE, et al. Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg. Aug 1987;67(2):224-30. [Medline].
Preul MC, Caramanos Z, Villemure JG, et al. Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery. Feb 2000;46(2):306-18. [Medline].
Shimizu KT, Tran LM, Mark RJ, Selch MT. Management of oligodendrogliomas. Radiology. Feb 1993;186(2):569-72. [Medline].
Tice H, Barnes PD, Goumnerova L, Scott RM, Tarbell NJ. Pediatric and adolescent oligodendrogliomas. AJNR Am J Neuroradiol. Nov-Dec 1993;14(6):1293-300. [Medline].
Viader F, Derlon JM, Petit-Taboué MC, et al. Recurrent oligodendroglioma diagnosed with 11C-L-methionine and PET: a case report. Eur Neurol. 1993;33(3):248-51. [Medline].
Further Reading
Related eMedicine topics:
Oligodendroglioma (from Neurology)
Neoplasms, Brain
Brain, Metastases
Brainstem Gliomas
EEG in Brain Tumors
Keywords
oligodendroglioma, oligodendroglial cells, oligodendrocyte, oligodendroglial tumor cells, cerebral oligodendroglioma, oligodendroglia, intramedullary oligodendrogliomas, primary leptomeningeal oligodendrogliomas, Kernohan grading system, Smith grading system, Ringertz grading system, Saint Anne/Mayo (St. Anne-Mayo) grading system, Daumas-Duport grading system
